BACKGROUND: The efficacy of antimicrobial treatment in children with acute otitis media remains controversial. METHODS: In this randomized, double-blind trial, children 6 to 35 months of age with acute otitis media, diagnosed with the use of strict criteria, receivedamoxicillin-clavulanate (161 children) orplacebo (158 children) for 7 days. The primary outcome was the time to treatment failure from the first dose until the end-of-treatment visit on day 8. The definition of treatment failure was based on the overall condition of the child (including adverse events) and otoscopic signs of acute otitis media. RESULTS:Treatment failure occurred in 18.6% of the children who received amoxicillin-clavulanate, as compared with 44.9% of the children who received placebo (P<0.001). The difference between the groups was already apparent at the first scheduled visit (day 3), at which time 13.7% of the children who received amoxicillin-clavulanate, as compared with 25.3% of those who received placebo, had treatment failure. Overall, amoxicillin-clavulanate reduced the progression to treatment failure by 62% (hazard ratio, 0.38; 95% confidence interval [CI], 0.25 to 0.59; P<0.001) and the need for rescue treatment by 81% (6.8% vs. 33.5%; hazard ratio, 0.19; 95% CI, 0.10 to 0.36; P<0.001). Analgesic or antipyretic agents were given to 84.2% and 85.9% of the children in the amoxicillin-clavulanate and placebo groups, respectively. Adverse events were significantly more common in the amoxicillin-clavulanate group than in the placebo group. A total of 47.8% of the children in the amoxicillin-clavulanate group had diarrhea, as compared with 26.6% in the placebo group (P<0.001); 8.7% and 3.2% of the children in the respective groups had eczema (P=0.04). CONCLUSIONS:Children with acute otitis media benefit from antimicrobial treatment as compared with placebo, although they have more side effects. Future studies should identify patients who may derive the greatest benefit, in order to minimize unnecessary antimicrobial treatment and the development of bacterial resistance. (Funded by the Foundation for Paediatric Research and others; ClinicalTrials.gov number, NCT00299455.).
RCT Entities:
BACKGROUND: The efficacy of antimicrobial treatment in children with acute otitis media remains controversial. METHODS: In this randomized, double-blind trial, children 6 to 35 months of age with acute otitis media, diagnosed with the use of strict criteria, received amoxicillin-clavulanate (161 children) or placebo (158 children) for 7 days. The primary outcome was the time to treatment failure from the first dose until the end-of-treatment visit on day 8. The definition of treatment failure was based on the overall condition of the child (including adverse events) and otoscopic signs of acute otitis media. RESULTS: Treatment failure occurred in 18.6% of the children who received amoxicillin-clavulanate, as compared with 44.9% of the children who received placebo (P<0.001). The difference between the groups was already apparent at the first scheduled visit (day 3), at which time 13.7% of the children who received amoxicillin-clavulanate, as compared with 25.3% of those who received placebo, had treatment failure. Overall, amoxicillin-clavulanate reduced the progression to treatment failure by 62% (hazard ratio, 0.38; 95% confidence interval [CI], 0.25 to 0.59; P<0.001) and the need for rescue treatment by 81% (6.8% vs. 33.5%; hazard ratio, 0.19; 95% CI, 0.10 to 0.36; P<0.001). Analgesic or antipyretic agents were given to 84.2% and 85.9% of the children in the amoxicillin-clavulanate and placebo groups, respectively. Adverse events were significantly more common in the amoxicillin-clavulanate group than in the placebo group. A total of 47.8% of the children in the amoxicillin-clavulanate group had diarrhea, as compared with 26.6% in the placebo group (P<0.001); 8.7% and 3.2% of the children in the respective groups had eczema (P=0.04). CONCLUSIONS:Children with acute otitis media benefit from antimicrobial treatment as compared with placebo, although they have more side effects. Future studies should identify patients who may derive the greatest benefit, in order to minimize unnecessary antimicrobial treatment and the development of bacterial resistance. (Funded by the Foundation for Paediatric Research and others; ClinicalTrials.gov number, NCT00299455.).
Authors: Alejandro Hoberman; Jack L Paradise; Howard E Rockette; Diana H Kearney; Sonika Bhatnagar; Timothy R Shope; Judith M Martin; Marcia Kurs-Lasky; Susan J Copelli; D Kathleen Colborn; Stan L Block; John J Labella; Thomas G Lynch; Norman L Cohen; MaryAnn Haralam; Marcia A Pope; Jennifer P Nagg; Michael D Green; Nader Shaikh Journal: N Engl J Med Date: 2016-12-22 Impact factor: 91.245
Authors: K Vuorenoja; J Jalava; L Lindholm; P A Tähtinen; M K Laine; K Thorn; A Ruohola Journal: Eur J Clin Microbiol Infect Dis Date: 2011-07-30 Impact factor: 3.267
Authors: Joseph A Lewnard; Paula A Tähtinen; Miia K Laine; Laura Lindholm; Jari Jalava; Pentti Huovinen; Marc Lipsitch; Aino Ruohola Journal: J Infect Dis Date: 2018-09-22 Impact factor: 5.226
Authors: Alejandro Hoberman; Jack L Paradise; Howard E Rockette; Jong-Hyeon Jeong; Diana H Kearney; Sonika Bhatnagar; Timothy R Shope; Gysella Muñiz; Judith M Martin; Marcia Kurs-Lasky; MaryAnn Haralam; Marcia A Pope; Jennifer P Nagg; Wenchen Zhao; Mohammad Kowser Miah; Jan Beumer; Raman Venkataramanan; Nader Shaikh Journal: Antimicrob Agents Chemother Date: 2017-06-27 Impact factor: 5.191